Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, today announced that CEO Dr. James A. Hayward and leadership of the Company’s majority-owned subsidiary, LineaRx, Inc., will be meeting with members of the global investment community from January 13 to 15, 2020 in San Francisco concurrent with the JP Morgan 38thAnnual Healthcare Conference, the world’s largest healthcare investment symposium.
In addition, Dr. Hayward will present an overview of the Company, including its supply chain platform, its diagnostic platform for the blood-based capture of metastatic cells, and review the linear DNA platforms in nucleic acid delivery, gene expression, non-integrated DNA replication, and its robust pipeline of more than 15 contract research opportunities with top cancer, gene therapy, vaccine and RNA partners at the Biotech Showcase 2020 at 3:00 pm PT on Tuesday, January 14, 2020. Dr. Hayward’s presentation will be webcast live at: https://event.webcasts.com/starthere.jsp?ei=1279407&tp_key=6924765b8a .
About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture. LineaRx is also developing a liquid biopsy form for isolating metastatic cells from blood. Go to www.adnas.com for more information on LineaRx and to learn more about how Applied DNA makes life real and safe. LineaRx is a majority-owned Applied DNA Sciences, Inc. (Nasdaq: APDN) company.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn . Join our mailing list .
Common stock listed on NASDAQ under the symbol APDN.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s or its partners product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and other reports we file with the SEC, which are available at www.sec.gov . Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
應用DNA科學公司(納斯達克市場代碼:APDN)(“應用dna”或“公司”),基於聚合酶鏈式反應(Pcr)的dna製造技術領先,用於產品真實性、可追溯性解決方案、基於核酸的生物治療開發和用於癌症診斷的液體活檢。該公司首席執行官詹姆斯·A·海沃德博士(James A.Hayward)和該公司控股子公司萊納羅克斯公司(LineaRx,Inc.)的領導人將於2020年1月13日至15日在舊金山與JP摩根第38屆年度醫療保健會議(全球最大的醫療投資研討會)同時舉行會議。
此外,海沃德博士還將介紹該公司的概況,包括其供應鏈平台、基於血液的轉移細胞捕獲診斷平台,以及在核酸傳遞、基因表達、非整合dna複製方面的線性dna平台,以及在2020年1月14日(星期二)下午3:00舉行的“生物技術展覽會”(Biotech Showcase 2020)上,它將提供超過15個與頂級癌症、基因治療、疫苗和RNA合作伙伴的合同研究機會。海沃德博士的演講將在網上直播:https://event.webcasts.com/starthere.jsp?ei=1279407&tp_key=6924765b8a。
關於LineaRx
LineaRx尋求將應用DNA在大規模聚合酶鏈反應(“PCR”)設計、製造和化學修飾方面的豐富專業知識和經驗的生物治療價值商業化。線性DNA是DNA的一種形式,它不同於DNA的圓形,最常見的是在質粒中產生,在細菌中生長。質粒是在細菌中發現的染色體外DNA,與細菌間經常交換的抗生素抗藥性基因相關,因而被許多人認為是對全球健康的嚴重威脅。此外,許多核酸療法也依賴病毒載體高效轉染和表達質粒DNA。這些病毒載體帶來了額外的非平凡風險,而且非常耗時,而且製造成本也很高。LineaRx還在開發一種液體活檢表格,用於從血液中分離轉移細胞。有關LineaRx的更多信息,請訪問www.adnas.com,瞭解更多關於應用DNA如何讓生命變得真實和安全的信息。LineaRx是一家多數股權的應用DNA科學公司。(納斯達克市場代碼:APDN)
關於應用DNA科學
應用dna是一家提供分子技術的供應商,這些技術支持供應鏈安全、防偽和防盜技術、產品基因分型和臨牀前核酸治療藥物候選產品。
應用dna通過提供創新的、基於分子的技術解決方案和服務,幫助保護公司、政府和消費者的產品、品牌、整個供應鏈和知識產權免遭盜竊、偽造、欺詐和轉移,從而使生活變得真實和安全。
欲瞭解更多信息,請訪問adnas.com。在Twitter和LinkedIn上關注我們。加入我們的郵件列表。
在納斯達克上市的普通股代號為APDN。
前瞻性陳述
應用脱氧核糖核酸在本新聞稿中所作的陳述,可屬1933年“證券法”第27A條、1934年“證券交易法”第21E條及1995年“私人證券訴訟改革法”所指的“前瞻性”性質。前瞻性陳述描述了應用dna的未來計劃、預測、策略和預期,基於假設,涉及許多風險和不確定因素,其中許多風險和不確定性超出了應用dna的控制範圍。實際結果可能與預測的結果大不相同,原因是可能無法及時支付其未兑現的有擔保可轉換票據,並因此由票據持有人強制執行抵押品補救辦法,其中主要包括應用DNA的所有資產、淨虧損的歷史、有限的財政資源、有限的市場接受程度、研究和開發中固有的不確定性、未來的臨牀數據和分析,包括任何應用DNA或其合作伙伴的產品候選人是否會在臨牀前研究或臨牀試驗過程中取得進一步進展,包括獲得美國食品和藥物管理局或同等外國監管機構的許可進行臨牀試驗,以及是否和何時進行臨牀試驗,它們將獲得美國FDA或同等外國監管機構的最終批准,以及應用DNA的SEC報告和文件中不時詳述的其他各種因素,包括我們於2019年12月12日提交的10-K表格的年度報告,以及我們向SEC提交的其他報告,這些報告可在www.sec.gov上查閲。除法律另有規定外,應用dna沒有義務公開更新任何前瞻性陳述,以反映本合同日期後的新信息、事件或情況,或反映意外事件的發生。